These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 30126000)

  • 21. Elevated preoperative plasma D-dimer level is a useful predictor of chemoresistance and poor disease outcome for serous ovarian cancer patients.
    Liu P; Wang Y; Tong L; Xu Y; Zhang W; Guo Z; Ni H
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1163-71. PubMed ID: 26542279
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Identification and prognostic value of differentially expressed proteins of patients with platinum resistance epithelial ovarian cancer in serum].
    Wu WJ; Wang Q; Zhang W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2016 Jul; 51(7):515-23. PubMed ID: 27465871
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantitative metabolic parameters measured on F-18 FDG PET/CT predict survival after relapse in patients with relapsed epithelial ovarian cancer.
    Kim CY; Jeong SY; Chong GO; Son SH; Jung JH; Kim DH; Lee SW; Ahn BC; Lee J
    Gynecol Oncol; 2015 Mar; 136(3):498-504. PubMed ID: 25557270
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Novel 18-Marker Panel Predicting Clinical Outcome in Breast Cancer.
    Biermann J; Nemes S; Parris TZ; Engqvist H; Rönnerman EW; Forssell-Aronsson E; Steineck G; Karlsson P; Helou K
    Cancer Epidemiol Biomarkers Prev; 2017 Nov; 26(11):1619-1628. PubMed ID: 28877888
    [No Abstract]   [Full Text] [Related]  

  • 25. A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging.
    Skírnisdóttir I; Seidal T; Sorbe B
    Int J Gynecol Cancer; 2004; 14(2):259-70. PubMed ID: 15086725
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer.
    Gong C; Tan W; Chen K; You N; Zhu S; Liang G; Xie X; Li Q; Zeng Y; Ouyang N; Li Z; Zeng M; Zhuang S; Lau WY; Liu Q; Yin D; Wang X; Su F; Song E
    EBioMedicine; 2016 Sep; 11():199-209. PubMed ID: 27566954
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy.
    Previs RA; Bevis KS; Huh W; Tillmanns T; Perry L; Moore K; Chapman J; McClung C; Kiet T; Java J; Chan J; Secord AA
    Gynecol Oncol; 2014 Mar; 132(3):531-6. PubMed ID: 24472410
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Melanoma long non-coding RNA signature predicts prognostic survival and directs clinical risk-specific treatments.
    Chen X; Guo W; Xu XJ; Su F; Wang Y; Zhang Y; Wang Q; Zhu L
    J Dermatol Sci; 2017 Mar; 85(3):226-234. PubMed ID: 27955882
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum microRNA expression signatures identified from genome-wide microRNA profiling serve as novel noninvasive biomarkers for diagnosis and recurrence of bladder cancer.
    Jiang X; Du L; Wang L; Li J; Liu Y; Zheng G; Qu A; Zhang X; Pan H; Yang Y; Wang C
    Int J Cancer; 2015 Feb; 136(4):854-62. PubMed ID: 24961907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preoperative red cell distribution width and neutrophil-to-lymphocyte ratio predict survival in patients with epithelial ovarian cancer.
    Li Z; Hong N; Robertson M; Wang C; Jiang G
    Sci Rep; 2017 Feb; 7():43001. PubMed ID: 28223716
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of p21, p21 p27 and p21 p53 status to histological subtypes and prognosis in low-stage epithelial ovarian cancer.
    Skirnisdottir I; Seidal T
    Cancer Genomics Proteomics; 2013; 10(1):27-34. PubMed ID: 23382584
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
    Canaz E; Grabowski JP; Richter R; Braicu EI; Chekerov R; Sehouli J
    Gynecol Oncol; 2019 Sep; 154(3):539-546. PubMed ID: 31230821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comprehensive Transcriptome Profiling Reveals Multigene Signatures in Triple-Negative Breast Cancer.
    Liu YR; Jiang YZ; Xu XE; Hu X; Yu KD; Shao ZM
    Clin Cancer Res; 2016 Apr; 22(7):1653-62. PubMed ID: 26813360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. POZ/BTB and AT-Hook-Containing Zinc Finger Protein 1 (PATZ1) Suppresses Progression of Ovarian Cancer and Serves as an Independent Prognosis Factor.
    Zhao C; Yan M; Li C; Feng Z
    Med Sci Monit; 2018 Jun; 24():4262-4270. PubMed ID: 29926841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer.
    Kandimalla R; Gao F; Matsuyama T; Ishikawa T; Uetake H; Takahashi N; Yamada Y; Becerra C; Kopetz S; Wang X; Goel A
    Clin Cancer Res; 2018 Aug; 24(16):3867-3877. PubMed ID: 29514841
    [No Abstract]   [Full Text] [Related]  

  • 36. CD44 as a cancer stem cell marker and its prognostic value in patients with ovarian carcinoma.
    Bartakova A; Michalova K; Presl J; Vlasak P; Kostun J; Bouda J
    J Obstet Gynaecol; 2018 Jan; 38(1):110-114. PubMed ID: 28816557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of biomarkers associated with diagnosis and prognosis of colorectal cancer patients based on integrated bioinformatics analysis.
    Chen L; Lu D; Sun K; Xu Y; Hu P; Li X; Xu F
    Gene; 2019 Apr; 692():119-125. PubMed ID: 30654001
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma.
    Guo W; Zhu L; Yu M; Zhu R; Chen Q; Wang Q
    Clin Epigenetics; 2018 Nov; 10(1):142. PubMed ID: 30446011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A robust panel based on tumour microenvironment genes for prognostic prediction and tailoring therapies in stage I-III colon cancer.
    Zhou R; Zeng D; Zhang J; Sun H; Wu J; Li N; Liang L; Shi M; Bin J; Liao Y; Huang N; Liao W
    EBioMedicine; 2019 Apr; 42():420-430. PubMed ID: 30917936
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CDKN3 is an independent prognostic factor and promotes ovarian carcinoma cell proliferation in ovarian cancer.
    Li T; Xue H; Guo Y; Guo K
    Oncol Rep; 2014 Apr; 31(4):1825-31. PubMed ID: 24573179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.